NCT07015853
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Start date: Jun 2026 to Dec 2026
- Eligibility criteria expanded, about 34 words
- Primary and study completion pushed from Jul 2033 to Dec 2033
- Secondary endpoints: details revised at 4 of 4 entries
- Site details revised
- Collaborators: details revised at 1 of 2 entries
- Notable Primary and study completion dates: Dec 2032 to Jul 2033
- Start date: Sep 2025 to Jun 2026
- Notable Start date: Jul 2025 to Sep 2025
- Primary and study completion dates: Oct 2032 to Dec 2032
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Overall Response Rate (ORR)
Timeframe: From start of study treatment until subject proceeds to standard of care treatment, up to 2 years.
Secondary (4)
Number of Adverse Events Related to Study Treatment
Progression-free survival (PFS)
Overall Survival (OS)
Duration of Response (DoR)
Arms and interventions
Pembrolizumab, Radiotherapy, AxatilimabExperimental
Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. Radiotherapy, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.
Drugs: Pembrolizumab, Axatilimab
Radiation: Radiotherapy
Sites
1 site in 1 country
- Cedars-Sinai Medical CenterLos Angeles, California, United States